Axsome Therapeutics’ US$225 Million Shares Public Offering

DLA Piper advised Axsome Therapeutics on the offering.Axsome Therapeutics, Inc. (Axsome), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Laura Testa

Author: Laura Testa

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here